Industry

Introduces New Model That Delivers Greater Coding Precision and Automation to Reduce Errors, Accelerate Payments, and Close the Loop Between Care and Revenue REDWOOD CITY, Calif.–(BUSINESS WIRE)–Suki, the leader in artificial intelligence (AI) technology for healthcare, today announced its expansion of assisted revenue cycle capabilities powered by ambient clinical intelligence models that significantly improve a … [Read more…]

New data examining fosfomycin for injection’s ability to treat acute pyelonephritis (AP) and complicated urinary tract infections (cUTIs) to be presented in three poster sessions Additional analyses from Phase 2/3 ZEUS clinical trial of fosfomycin for injection for cUTI to be shared Breadth of data presented demonstrates fosfomycin for injection’s effectiveness in combatting infections and … [Read more…]

HOUSTON–(BUSINESS WIRE)–Bayou Surgical, innovators in intraoperative visualization, today announces the launch of its new 5mm troCarWash™ system — the newest and most advanced automated laparoscope cleaning solution designed to maintain clear vision during minimally invasive surgery (MIS) without removing the scope from the surgical field. The 5mm troCarWash™ builds on Bayou’s existing 10mm platform, incorporating … [Read more…]

– Financing led by Perceptive Advisors with participation from new and existing biotech focused investors – – Alto expects to use the proceeds of this financing to accelerate development of ALTO-207 in Treatment Resistant Depression – MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–$anro #cns–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of … [Read more…]

Company to highlight recently FDA cleared AI Software for real-time intraoperative guidance in Transcatheter Aortic Valve Implantation (TAVI) NICE, France–(BUSINESS WIRE)–Caranx Medical (“Caranx”, a CarvOlix group company), a French medical device company specializing in the development of an autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, will showcase updates … [Read more…]

– FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data – – Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomized Phase III study – – Lupus nephritis affects more than … [Read more…]

TOKYO & HAYWARD, Calif.–(BUSINESS WIRE)–Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain other territories in Asia (excluding mainland China). This … [Read more…]

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancer Planned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026 Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical … [Read more…]

Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC: Median PFS of 11.14 Months vs. 6.90 Months, Respectively, for Patients Receiving Ivonescimab Plus Chemotherapy vs. Tislelizumab Plus Chemotherapy; Hazard Ratio of 0.60 … [Read more…]

First presentation of clinical data from the sixth DXd antibody drug conjugate from the oncology pipeline of Daiichi Sankyo Early results support continued development of DS-3939, a potential first-in-class TA-MUC1 directed antibody drug conjugate TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Initial results from the dose escalation part of the first-in-human phase 1/2 trial of DS-3939 demonstrated … [Read more…]